Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin and allopurinol in infants with hypoxic-ischemic encephalopathy
IRCT20110807007244N11Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of erythropoietin and allopurinol in hypoxic-ischemic encephalopathy (HIE) (4 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Change in prooxidant-antioxidant balance, Change in interleukin-6 and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
erythropoietinallopurinol
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on IRCT20110807007244N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20110807007244N11.